肾移植受者感染COVID-19后尽管免疫抑制调整,新发供者特异性抗体发生率仍低
该研究纳入2家法国机构的179例肾移植受者,在COVID-19前后进行抗HLA抗体筛查。感染后供者特异性抗体(DSA)发生率为4%(住院者8% vs 非住院者0%),排斥反应3例(1.7%),均发生在住院患者。尽管抗代谢药中断47%、钙调神经磷酸酶抑制剂中断12%,DSA发生率仍低,且主要局限于高危免疫状态患者。
要点
- COVID-19后DSA发生率4%,住院者8% vs 非住院者0%。
- 抗代谢药中断47%,钙调神经磷酸酶抑制剂中断12%。
- 排斥反应3例(1.7%),均发生于住院患者。
核心结论
- COVID-19阳性肾移植受者中,COVID-19后DSA发生率低(4%),尽管免疫抑制显著减少,且主要局限于高危免疫状态患者。
- COVID-19严重程度与COVID-19后DSA和/或排斥反应无关。
研究设计与样本
- 来自2家法国机构的肾移植受者,在COVID-19前后进行抗HLA抗体筛查。
- 记录免疫抑制管理、排斥反应、COVID-19严重程度、炎症标志物和抗病毒治疗。
- 招募251例,排除COVID-19相关死亡25例和免疫学随访不完整47例,最终纳入179例。
主要发现
- 住院患者占49.2%。
- 抗代谢药中断47%(住院者82%,中位恢复时间23天;非住院者15%,中位恢复时间7天)。
- 钙调神经磷酸酶抑制剂中断12%(均为住院患者,中位恢复时间11天)。
- COVID-19后DSA发生率为4%(住院者8% vs 非住院者0%)。
- 排斥反应3例(1.7%),均为住院患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Decreased immunosuppression has been proposed for kidney transplant recipients infected with coronavirus disease 2019 (COVID-19), but the impact on the alloreactive immune response during and after infection has been poorly investigated. We evaluated the occurrence of antihuman leukocyte antigen (HLA) donor-specific antibodies (DSAs) (post-COVID-19) and rejection episodes after COVID-19 with particular focus on immunosuppression modulation. METHODS: Kidney transplant recipients from 2 French institutions had anti-HLA antibody screening before and after COVID-19. Management of immunosuppression, rejection episodes, COVID-19 severity, inflammatory markers, and antiviral therapies were recorded. RESULTS: From 251 recruited patients, 72 were excluded because of COVID-19-related death (n = 25) and incomplete immunologic follow-up (n = 47). Among the remaining 179 included patients, almost half were hospitalized (49.2%). Antimetabolites were interrupted in 47% of patients (82% in hospitalized, median time of resumption of 23 days and in 15% nonhospitalized, median time of resumption of 7 days). Calcineurin inhibitors were interrupted in 12% of patients (all hospitalized, median time of resumption of 11 days). The incidence of post-COVID-19 DSA was 4% (8% and 0% in hospitalized and nonhospitalized, respectively). Allograft rejection occurred in 3 patients (1.7%) and all were hospitalized. Younger age, transplantation <1 year, and preexisting DSA were more frequently observed in patients with post-COVID-19 DSA, whereas inflammatory markers, lymphopenia, and use of antiviral therapies were not. CONCLUSION: The incidence of post-COVID-19 DSA among COVID-19-positive kidney transplant recipients was low (4%) despite a significant decrease in immunosuppression and was mainly restricted to high-risk immunologic patient's status. COVID-19 severity was not associated with post-COVID-19 DSA and/or rejection.
引用
- Masset C, Gautier-Vargas G, Cantarovich D, et al. Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation. Kidney Int Rep. 2022. PMID: 35155848. doi:10.1016/j.ekir.2022.01.1072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。